Biogen Addressing Avonex Liquid Formulation Manufacturing Problems
This article was originally published in The Pink Sheet Daily
Executive Summary
Pre-filled syringe process is experiencing a "technical issue" on the fill-finish side. Biogen has the option to ramp up production of Avonex' original lyophilized powder formulation to make up for shortages on the liquid side.
You may also be interested in...
Avonex Syringe Component Approval Is "Good News" Despite Charge, Biogen Idec Says
FDA's approval in March of a new component for the pre-filled syringe is "good news" for the MS therapy but resulted in a first quarter charge of $11 mil. for finished product that is no longer needed, the company says. Avonex sales grew 5.4% during the quarter, driven by international gains.
Avonex Syringe Component Approval Is "Good News" Despite Charge, Biogen Idec Says
FDA's approval in March of a new component for the pre-filled syringe is "good news" for the MS therapy but resulted in a first quarter charge of $11 mil. for finished product that is no longer needed, the company says. Avonex sales grew 5.4% during the quarter, driven by international gains.
Avonex Manufacturing Update: New Liquid Fill-Finish Process Validated
Biogen Idec has completed validation of a new fill-finish process for the liquid formulation of Avonex.